HK Inno.N Corp.
HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hyperc… Read more
HK Inno.N Corp. (195940) - Net Assets
Latest net assets as of September 2025: ₩1.29 Trillion KRW
Based on the latest financial reports, HK Inno.N Corp. (195940) has net assets worth ₩1.29 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.17 Trillion) and total liabilities (₩872.89 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.29 Trillion |
| % of Total Assets | 59.72% |
| Annual Growth Rate | 10.17% |
| 5-Year Change | 68.37% |
| 10-Year Change | N/A |
| Growth Volatility | 19.39 |
HK Inno.N Corp. - Net Assets Trend (2018–2024)
This chart illustrates how HK Inno.N Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HK Inno.N Corp. (2018–2024)
The table below shows the annual net assets of HK Inno.N Corp. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.25 Trillion | +3.97% |
| 2023-12-31 | ₩1.20 Trillion | +3.39% |
| 2022-12-31 | ₩1.16 Trillion | +1.15% |
| 2021-12-31 | ₩1.15 Trillion | +54.86% |
| 2020-12-31 | ₩743.23 Billion | +4.34% |
| 2019-12-31 | ₩712.30 Billion | +1.81% |
| 2018-12-31 | ₩699.66 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to HK Inno.N Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 21959745221000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩207.69 Billion | 16.60% |
| Common Stock | ₩14.45 Billion | 1.15% |
| Other Components | ₩1.03 Trillion | 82.25% |
| Total Equity | ₩1.25 Trillion | 100.00% |
HK Inno.N Corp. Competitors by Market Cap
The table below lists competitors of HK Inno.N Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
$512.27 Million |
|
Suzhou Keda Technology Co Ltd
SHG:603660
|
$512.28 Million |
|
Jiangsu Lianyungang Port Co Ltd
SHG:601008
|
$512.48 Million |
|
Gansu Golden Glass Technologies Co Ltd
SHE:300093
|
$512.56 Million |
|
Zhejiang Transfar Co Ltd
SHE:002010
|
$512.22 Million |
|
Malaysia Building Society Bhd
KLSE:1171
|
$512.21 Million |
|
KMRIF
PINK:KMRIF
|
$512.11 Million |
|
Chutian Dragon Co Ltd
SHE:003040
|
$512.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HK Inno.N Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,203,646,389,260 to 1,251,377,196,400, a change of 47,730,807,140 (4.0%).
- Net income of 61,580,192,970 contributed positively to equity growth.
- Dividend payments of 5,650,362,200 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩61.58 Billion | +4.92% |
| Dividends Paid | ₩5.65 Billion | -0.45% |
| Other Changes | ₩-8.20 Billion | -0.66% |
| Total Change | ₩- | 3.97% |
Book Value vs Market Value Analysis
This analysis compares HK Inno.N Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.07x to 1.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩24205.90 | ₩50200.00 | x |
| 2019-12-31 | ₩24643.26 | ₩50200.00 | x |
| 2020-12-31 | ₩25713.29 | ₩50200.00 | x |
| 2021-12-31 | ₩39819.21 | ₩50200.00 | x |
| 2022-12-31 | ₩41095.16 | ₩50200.00 | x |
| 2023-12-31 | ₩42486.80 | ₩50200.00 | x |
| 2024-12-31 | ₩44171.62 | ₩50200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HK Inno.N Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.86%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.51x
- Recent ROE (4.92%) is above the historical average (2.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -1.22% | -2.54% | 0.22x | 2.15x | ₩-78.49 Billion |
| 2019 | 1.86% | 2.45% | 0.33x | 2.28x | ₩-58.01 Billion |
| 2020 | 3.75% | 4.66% | 0.37x | 2.17x | ₩-46.43 Billion |
| 2021 | 2.15% | 3.21% | 0.42x | 1.60x | ₩-90.36 Billion |
| 2022 | 3.28% | 4.50% | 0.47x | 1.55x | ₩-78.29 Billion |
| 2023 | 3.92% | 5.69% | 0.45x | 1.54x | ₩-73.17 Billion |
| 2024 | 4.92% | 6.86% | 0.47x | 1.51x | ₩-63.56 Billion |
Industry Comparison
This section compares HK Inno.N Corp.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HK Inno.N Corp. (195940) | ₩1.29 Trillion | -1.22% | 0.67x | $512.24 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |